Mike Waring
Newcastle University
Biography
Mike Waring is Chair of Medicinal Chemistry at Newcastle University and Head of Chemistry for the Cancer Research UK Newcastle Drug Discovery Unit. He was previously Principal Scientist in Medicinal Chemistry at AstraZeneca. He has worked mainly in the areas of diabetes and oncology and his work has contributed to the discovery of 14 drug candidates, including the marketed EGFR inhibitor osimertinib (Tagrisso™).
He has made significant contributions to the field in many areas, perhaps most notably property-based optimisation, covalent inhibition, novel binding modes and new methods of hit generation. He is a 2018 American Chemical Society Hero of Chemistry and recipient of the 2017 RSC Malcolm Campbell Medal. He is an elected fellow of the Royal Society of Chemistry.
RSC affiliations
Editor-in-Chief, RSC Medicinal Chemistry